The paper contributes to an emerging literature that critically questions the degree to which R&D, at the centre of national and transnational innovation policies, results in firm growth. The differences in how innovation affects firm growth is explored for small and large publicly quoted US pharmaceutical firms between 1950 and 2008. We observe that the positive impact of R&D on firm growth is highly conditional upon a combination of firm-specific characteristics such as firm size, patenting and persistence in patenting. For small firms, R&D boosts growth for only a subset of firms: namely, those that patent persistently for a minimum of five years. For large pharmaceutical firms, on the other hand, R&D may have a negative impact on growth; potentially resulting from the low R&D productivity these firms have suffered from since the mid-1990s. These results raise important issues around the R&D and firm growth relationship for small and large firms as well the role of persistence in innovation for boosting firm performance.
Introduction
The theoretical literature on the economics of innovation suggests that there is a direct causal link between innovation and economic growth. Innovation is often seen as one of the most important means through which firms compete and grow, especially in the current era of the knowledge economy (Mason et al., 2009) . This belief has unsurprisingly translated into economic policies aimed at innovation-led growth. Thus, policymakers attach great importance to innovation activities such as business R&D and patenting (see, for example, DIUS Annual Innovation Report, 2008) .
Despite this common assumption of Schumpeterian and more mainstream industrial economists that it is the more innovative and efficient firms that will grow more (Nelson and Winter, 1982) , surprisingly few empirical studies show that innovation is successful in boosting firms' growth performance. Some studies have found a positive impact of innovation on growth (Geroski and Machin, 1992; Geroski and Toker, 1996; Yasuda, 2005) while others no significant impact (Almus and Nerlinger, 1999; Bottazzi et al., 2001; Lö ö f and Heshmati, 2006) , and still others even a negative impact (Brouwer et al., 1993; Freel and Robson, 2004) . This inconclusiveness in the literature raises a general question of market selection: "Do markets 'reward' the 'most innovative' firms?" as well as a more specific question related to the economic returns to R&D: "Given its huge costs, is R&D worth it? " 1 These questions are of utmost relevance to innovation and competition policies. The European Commission's EC 2020 agenda advocates that firms should spend more on R&D with a target of 3 per cent of GDP in aggregate figures. However, if R&D does not necessarily boost firm growth as suggested by the mixed empirical evidence, and if innovative firms do not outperform non-innovative firms, it may be potentially dangerous to ask firms to spend more on R&D.
To provide insights into these questions, we investigate the relationship between R&D and sales growth in the context of the pharmaceutical industry and explore whether markets reward innovators with a growth premium or whether only certain types of firms are rewarded for undertaking R&D. We focus on pharmaceutical firms quoted on the US stock market from 1950 to 2008. The pharmaceutical industry is a particularly interesting industry to study this question since the number of really innovative new drugs (New Molecular Entities) has remained relatively low despite the exponential increase of R&D spending and patents since the 1980s 2 -leading to a sort of "R&D paradox" 3 illustrated in Figure 1 .
We focus on how different firm characteristics affect the impact of R&D on firm growth. These characteristics, chosen due to their relevance in the innovation literature, are (i) firm size, (ii) firm patenting and (iii) persistent patenting (five years in a row). Furthermore, as the characteristics of the innovation process, as well as patenting laws, have undergone fundamental changes largely attributed to advances in genomics and IT and the 1980 Bayh -Dole Act (Gambardella, 1995) , we test whether the changes in the "innovation regime" have affected the R&D -growth relationship over time. The fact that the latter period in the industry history was characterized by a new division of innovative labour between large and small firms (Arora and Gambardella, 1994 )-with large pharmaceutical firms focusing more on the marketing and distribution efforts around new drugs, while small dedicated firms, often biotech related, focus on the more uncertain process of innovation around niche drugs-makes the investigation of the growth dynamics of large vs. small pharmaceutical firms particularly interesting.
Our results indicate that it can be very misleading to assume that R&D will always translate into growth for companies. We identify a general positive impact of R&D on firm growth at the industry level but a closer look into this relationship for different types of firms reveals that the positive impact of R&D is limited to only certain types of firms. We find that small pharmaceutical firms are more likely to grow as a result of their R&D efforts, but this growth is conditional on the firms patenting persistently. For large firms, on the other hand, our results suggest that R&D fails to boost growth and even has a negative effect on large firms' growth performance. These results are discussed and interpreted with reference to the main debates in the literature on the innovation-growth relationship and falling R&D productivity in the pharmaceutical industry.
The paper is organized as follows. Section 2 briefly reviews the literature that considers the impact of innovation on firm growth and discusses the empirical focus of the paper. Section 3 reviews the data and methodology used in the study. Section 4 discusses the results while Section 5 concludes.
Innovation and Firm Growth
The patterns and sources of firm growth continue to puzzle economists and management scholars due to the amount of mixed evidence on the structure of growth and the variety of sources that drive growth (Westhead and Birley, 1995) . This literature often goes back to the influential work of Gibrat (1931) , who proposed that the commonly found skewed distribution of firm size results from a process in which the proportionate rate of growth is a purely stochastic (random) variable whose mean is independent of firm size. Empirical studies in this line of work find that Gibrat's growth model is capable of "roughly" reproducing the empirical regularity of skewed firm size distributions. Yet, the growth process commonly shows indications of a more complicated structure in the form of mean reversion, a negative relationship between firm size and the variance of firm growth as well as autocorrelation in growth rates (see Sutton, 1997, for a general review, and Mazzucato, 2002, for an application to the industry life cycle). The specific empirical work on firm growth that our paper builds on most closely, is an emerging literature that acknowledges that the impact of innovation on growth is indeed different for different types of firms, such as for slow and fast growing firms (Coad and Rao, 2008; Hö lzl, 2009; Mason et al., 2009) ; firms with different levels of R&D intensity (Del Monte and Papagni, 2003) ; firms from low-tech and high-tech industries (Stam and Wennberg, 2009) ; and firms with a focus on product or process innovations (Brouwer et al., 1993) . Given the heterogeneity in firms' innovative activities within an industry and within size classes, it is important to understand whether and how firm-level differences shape the impact of innovation on firm growth.
Inspired by this literature to study the impact of innovation on firm growth, we focus on: (1) innovative differences between size classes and (2) innovative differences within size classes.
Innovative Differences between Size Classes
Innovative characteristics of firms differ by size. In general, small and large firms conduct different types of innovative activities that vary in scale, scope and efficiency. This is especially true in the pharmaceutical industry where a new "division of innovative labour" emerged, since the 1980s, in which small biotechnology companies and small pharmaceutical firms focus on niche areas of new molecular entity discovery while large pharmaceutical firms focus on the development side of the R&D equation as well as the marketing of the drugs.
Small firms, in different industries, tend to be better at "radical" product innovations while large firms, especially during the "mature" phase of the industry life cycle, excel in process innovations and incremental changes to established technologies (Klepper, 1996) . Small firms also differ from large firms by conducting innovations on a less persistent basis (Geroski et al., 1997; Cefis, 2003) and undertaking more informal R&D that is distributed among various operational units (Santarelli and Sterlacchini, 1990) .
As can be seen in Figure 2 , the number of small pharmaceutical firms has increased substantially over the years. The increased entry rates of small firms in this industry is often attributed to the Bayh -Dole Act (1980), which made it possible for universities to patent publicly funded inventions and led university scientists to form small spin-off biopharmaceutical firms. Moreover, as Figure 3 illustrates, the share of small patentee firms increased over time, highlighting the growing innovative capacity of small pharmaceutical firms. The new small pharmaceutical firms were able to undertake focused research in new areas such as pharmacogenomics and various forms of combinatorial chemistry that were not in the research domain of large and established firms (Drews, 2001) . This resulted in an ever growing symbiotic research relationship between small and large pharmaceutical firms making the pharmaceutical industry by far the most intensive sector in terms of contractual partnering among firms (Hagedoorn, 2002) . Quere (2003) argues that the emergence of small pharmaceutical and biotechnology firms caused a major R&D organizational reshuffling as the boundaries between small and large firms became fuzzier and large firms started substituting externally created knowledge with internally created knowledge. The different nature and scale of R&D conducted by small and large pharmaceutical firms leads us to believe that the impact of R&D upon growth may be different for these two types of firms.
Innovative Differences within Size Classes
Secondly, the innovative activities of firms are not only different between size classes but also within size classes. Among firms of the same size, some firms innovate while many others do not (Nelson and Winter, 1982) . Even among the innovators, there exists a wide range of differences in R&D capabilities, sources of innovation (e.g. suppliers/customers/scientific developments), degrees of innovativeness and innovative persistence (Utterback and Suárez, 1993) .
Persistence in innovative activities within an industry determines the degree to which innovations build on existing knowledge and capabilities, and consequently, whether the identity of innovators persists over time (i.e. the probability of established innovators being replaced by new ones). Many studies have found that most innovating firms tend to innovate occasionally rather than persistently (Geroski et al., 1997) . The few persistent innovators, however, are the source of the majority of innovations in each industry (Cefis, 2003) . Figure 4 shows the heterogeneity in the patenting capabilities within the size classes of small and large pharmaceutical firms. While there are a large number of firms that do not patent (i.e. non-patentees) in each size category, only a portion of the patentee firms patent persistently (i.e. persistent) for five consecutive years. In what follows, we explore if (and when) differences in innovative characteristics of firms affect whether firms' R&D efforts lead to sales growth in the pharmaceutical industry. We test the relationship between R&D and firm growth conditional on firm size (i.e. for small and large firms), firm patenting activity (i.e. patentees vs. non-patentees) and whether a firm patents persistently for a minimum of five years (i.e. persistent patentees vs. non-persistent patentees). 4
Data and Methodology
The mixed evidence on whether (and how) innovation affects firm growth suggests that there is still much to learn about the innovation-firm growth relationship to improve our understanding of the conditions under which markets reward innovators with a growth premium. We approach the problem by building a simple firm growth model where the growth rate is regressed on the R&D stock of the firm while we control for firm size, lagged growth and the number of years a firm has been quoted on the stock exchange (a proxy for "age"). We investigate the impact of innovation on firm growth for small and large publicly quoted firms by testing the differences, within each size class, between patentee and nonpatentee firms as well as those between persistent patentees and non-persistent patentees. We also compare the relationship between R&D and growth during different phases of the industry's life cycle.
Data-set
The data on pharmaceutical firms comes from merging the COMPUSTAT and NBER patent databases (Hall et al., 2001; Hall et al., 2005) . We have used the COMPUSTAT database to extract annual sales, employment and R&D expenditures for all publicly quoted pharmaceutical firms in the USA, listed under the GICS Code 352020 5 between 1950 and 2008. 6 The majority of these firms are headquartered in the USA; though foreign firms (from 16 countries) quoted on the US stock markets are also included.
The use of the COMPUSTAT database allows us to build on a well-established and rich literature that investigates the determinants of firm performance using this database (Griliches, 1981; Hall et al., 2001 among many) . While the database limits our analysis to only the publicly quoted firms and excludes the very small firms, we are confident that this does not cause a serious selection bias for the paper. 7 The most innovative players that spend money on R&D in this particular industry are likely to be listed on the stock market regardless of their size or headquarters location. Konar and Cohen (2001) argue that the R&D and sales figures reported in COMPUSTAT may not be fully reliable. They point out that firm sales should be broken down by SIC code to better capture the activities of diversified firms. The unavailability of plant-level data in COMPUSTAT hinders our efforts to control for diversification in firms' activities and, we acknowledge that the sales of diversified pharmaceutical firms in our data-set may be unavoidably overestimated compared to non-diversified firms; a common pitfall of studies that use the COMPUSTAT database. R&D figures reported prior to 1972 may also be less reliable since R&D reporting was not compulsory prior to this date (Bound et al., 1984) . We control for this by checking whether the results are similar if the pre-1972 period is excluded from the analysis.
The NBER patent database is used to extract the number of patents per year for each firm. The patent data is used to classify firms into groups based on their innovative behaviour: patentees vs. non-patentees and persistent patentees vs. non-persistent patentees. Categories 1, 2, 2a and 2b in Table 1 include full definitions of patent-based firm categories used in this study. Since actual innovations in this industry are the new drugs (not patents), we use patents simply as a "signal" of a firm's innovative effort, along with its R&D spending. Categories 3 and 4 in Table 1 are based on employment and reflect firm size.
To account for mergers and acquisitions (M&A) that occurred between 1950 and 2008, we have screened six sources including Who Owns Whom, International Hoover's Company Profiles, International Corporate Affiliations, Directory Information, ABI US Business and US Company Capsules and made a note of all firms that were subject to an M&A. Using the "super-firms" methodology, we restructured the data-set by assuming that any two (or more) firms that merged between 1950 and 2008 merged from the database's start date and we united their firm-level data (see Bottazzi et al., 2001 for details of the "super-firms" methodology). Similarly, if a firm has spun off from another, the two firms are re-merged starting from the spin-off date. The final database is an unbalanced panel of 248 firms over the period 1950-2008.
Description of Variables
To measure the growth of firms, we concentrate on an output measure: the annual percentage change in sales. Sales variable S i;t is measured in logarithms (log S i;t ) for firm i in year t and is used as a proxy of firm size. The sales growth rate (gr i;t ) for firm i in year t is the change in firm sales from year t-1 to year t (i.e. gr i;t ¼ log S i;t 2 log S i;t21 ).
R&D stock (RDS i;t ) is defined as the stock of R&D 8 for firm i in year t normalized by the firm's sales in year t-1. We normalize the R&D stock variable with the lagged value of sales instead of the current year's sales to avoid potential problems that arise due to correlation between the right-hand side sales variable log S i;t and the denominator of the RDS i;t variable (Hall and Mairesse, 1995) .
Finally, we have constructed a "public age" variable (PubAge i;t ) that reflects the number of years the firm has been quoted on the stock exchange as in Brown et al. (2009) . This is a proxy for the firm's experience as a "publicly held" firm and is helpful in capturing the age differences between new and established firms as well as adjusting for the fact that IPOs have become easier for the innovative small science-based firms after 1980s.
The main descriptive statistics for Net Sales, Employment, R&D Expenditures and Public Age are presented in Table 2 .
Methodology
We study the relationship between innovation and firm growth by looking at the effect of lagged R&D stock on firm growth rates. We control for firm size, the past growth rate of the 
where log ðS i;t Þ refers to the logarithm of sales for firm i in year t, gr i;t refers to the growth rate of firm i in year t (which is estimated as gr i;t ¼ log ðS i;t Þ 2 log ðS i;t21 Þ), RDS i;t refers to the R&D stock of firm i in year t (normalized by the sales in year t 2 1) and log ðPubAge i;t Þ refers to the logarithm of the public age of firm i in year t.
Since the lagged dependent variable is included among the regressors in Equation 1, the OLS estimator is known to produce inconsistent estimates. To deal with this problem, we use the Arellano -Bond panel GMM estimator (Cameron and Trivedi, 2005) . Furthermore, we recognize that a firm's R&D investment is an endogenous strategy that is implemented on the basis of the costs and potential outcomes of R&D as well as the institutional, legal and economic settings that determine the success and profitability of these outcomes (Grossman and Helpman, 1994) . To accommodate the endogenous nature of R&D investments, we treat this variable as endogenous and instrument it with its pre-determined values. Equation 1 is estimated for the whole sample as well as the subsamples based on categories described in Table 1 , including the combinations across innovation and firm size categories (such as small persistent patentees). We also look at the effect of R&D stock on growth in two different time periods, the period before and after 1984. Looking at these two periods allows us to ask whether the change in "innovation regime" affects the innovation-growth relationship.
Results and Analysis
This section presents the results where we explore the impact of firms' R&D stock on the growth of sales in different periods and for different types of firms. Table 3 contains the results for the relationship during the whole period : 1950-2008 and in specific sub-periods: 1972-83 and 1984-2008. The literature reports that innovation and intellectual property regimes relating to the US pharmaceutical industry have undergone drastic changes over this period (Gambardella, 1995; Malerba and Orsenigo, 2002) . Drug discovery techniques changed significantly starting from the early 1970s due to major developments in biology, genetic engineering, enzymology and bioinformatics (Henderson et al., 1999) . With these scientific advances, pharmaceutical scientists were able to identify the mechanisms by which the active compound of a drug binds to targets associated with diseases. This development opened up more structured avenues of research where one could design illustrations of "ideal" molecules that would cure certain diseases. The ability to design ideal molecules allowed scientific research to follow a more cumulative and systematic path. Starting from mid-1980s, the "drug discovery by design" gradually replaced the "random screening" processes that largely relied on trial and error and the innovation regime became more path-dependent and cumulative (Gambardella, 1995; Malerba and Orsenigo, 2002) . Simultaneously, the intellectual property regime evolved to become stronger in the 1980s and this encouraged universities and academics to assume a more entrepreneurial role in the industry (Arora and Gambardella, 1994) .
Despite the major shifts in the innovation and appropriability regimes, discussed in Sections 1 and 2, in our results, we observe that the effect of R&D on the growth of pharmaceutical firms does not change significantly: it remains positive and significant in both periods. This result is not very surprising given that pharmaceutical firms have always relied on high cost, complex R&D operations for the successful discovery of blockbuster drugs; commonly argued to be the biggest driver of pharmaceutical sales (Mahlich and Roediger-Schluga, 2006) .
When we include the patenting behaviour of firms as an additional way of stratifying our sample of firms, we find that regardless of whether a firm patents or not and whether the patenting activity is undertaken on a persistent (at least five consecutive years of patenting) or occasional basis, R&D still has a significant positive impact on the sales growth of firms (Table 4) .
We next control for firm size, and concentrate on small firms with less than 500 employees and study how R&D affects small pharmaceutical firms' sales growth in relation to their patenting activity. Here we find a big difference: R&D activities are crucial for the growth of small patentee firms; while for the small non-patentees, R&D is not a significant driver of sales growth. A further investigation of the small patentees reveals that R&D translates into sales growth for only the small persistent patentees while R&D has a significant negative impact on the growth performance of small non-persistent patentees (Table 5) .
Continuing the investigation of firm size, we next focus on large firms (over 500 employees). Here we find a significant and negative impact of R&D on the sales growth of large firms, regardless of whether they patent persistently or non-persistently. For the large non-patentees, we do not find a statistically significant relationship between R&D and sales growth (Table 6 ). In Table 7 , we summarize our findings for the impact of R&D on sales growth in the pharmaceutical industry. The most interesting finding is that while R&D has a general positive impact on the growth of firms at the aggregate industry level, it no longer has this Table 4 . The impact of R&D on sales growth based on patenting activities
Non-patentees
Patentees Persistent Non-persistent gr(t (1) 2 0.070*** 2 0.098*** 2 0.032*** 2 0.117*** (0.001) (0.000) (0.001) (0.000) RDS(t (1) 0.001*** 0.001*** 0.2^10 23 *** 0.001*** (0.000) (0.000) (0.000) (0.000) log(S)(t (1) 2 0.462*** 2 0.495*** 2 0.537*** 2 0.303*** (0.002) (0.000) (0.001) (0.001) log(PubAge) 0.045*** 0.031*** 0.043*** 0.017*** effect when firm size and the persistence of patenting are accounted for. It is only for small persistent patentees that R&D affects growth positively.
The innovation literature has highlighted the different R&D strategies of small and large pharmaceutical firms in the context of the "division of innovative labor" (Arora and Gambardella, 1994) . Small pharmaceutical firms are known for their specialism in upstream research while large firms focus on orchestrating the R&D efforts, commercialization processes, and clinical trials as well as marketing and regulatory activities (Audretsch and Thurik, 2001) . Our results bring an additional insight into why small and large firms specialize in different stages of the drug discovery process by highlighting that small firms are more likely to reap growth benefits through their R&D efforts. This finding relates to the commonly discussed issue of low R&D productivity among the large pharmaceutical firms. Paul et al. (2010, p. 203) reveal the seriousness of this problem by quoting that the ongoing R&D will help large pharmaceutical firms to generate only 26 cents with new product revenues for every $1 lost to generic competition due to patent expiry. Hence, the large pharmaceutical firms appear to fail in generating the innovative drugs that can drive their sales. Figure 5 which compares the R&D productivity (patents per $mil R&D) between small and large firms clearly reveals that large firms are experiencing lower R&D productivity. For small firms, we find that persistence in patenting is essential for R&D to translate into firm growth. Persistence in innovative activities, in particular patenting, has been widely discussed in the literature with the main emphasis centred on the existence and nature of innovative persistence and the reasons behind it (Geroski et al., 1997; Cefis, 2003; Peters, 2009 ). Our findings contribute to this literature by highlighting the role of innovative persistence for driving growth performance of firms. 9 In order to confirm the mediating effect of firm size in the R&D -firm growth relationship, we test whether an interaction term between firm size and R&D intensity is significant. We treat the R&D term and the interaction term of R&D and firm size endogenously. The results reported in Table 8 confirm that the interaction term is significant in all cases and has a negative sign for patentees and non-persistent patentees and a positive sign for all other Figure 5 . R&D productivity of small and large pharmaceutical firms. Source: Authors' calculations from NBER patent database and COMPUSTAT database. 9 We have also run a pooled model that includes interactions of the lagged R&D stock variable with the patenting dummy and persistent patenting dummy in order to assess whether the impact of R&D differs across these two key groups of firms. The results, not reported here, are available from the authors upon request and they confirm the accuracy of results presented in the separate regressions reported in the paper.
categories. This finding further confirms that firm size and innovative activities are crucial factors in determining the returns to R&D.
These results should be interpreted in light of the recent literature showing that there is a strong relationship between innovation and firm growth for certain types of firms and that fastest growing firms that contribute most to the economy are indeed some of the most innovative firms (NESTA, 2009 ).
Finally, the control variables suggest that firm size has a significant and negative impact on firm growth across all firm categories but especially for small firms; a result commonly found in firm growth studies (Evans, 1987; Sutton, 1997) . The "public age" variable, on the other hand, appears to have a positive impact on firm growth across all firm categories. We note that the positive sign of this variable is unexpected as previous studies report that the impact of age on growth is often negative suggesting that growth slows down as firms age (Evans, 1987; Dunne and Hughes, 1994) . A potential explanation to why the impact of public age is positive in our findings may relate to the positive associations of being "publicly held" for a longer period of time. Firms that start to float on the stock market are subject to relaxed financial constraints and financial constraints are well known to limit firm growth (Carpenter and Petersen, 2002) . Finally, the lagged growth performance of firms has a significant negative impact on firm growth.
Conclusions
The paper studies the role of R&D in driving firm growth in the US pharmaceutical industry between 1950 and 2008, a period during which the size composition of firms and the characteristics of innovation evolved significantly.
The paper was motivated by the fact that, although there are many national and transnational level policies that call for firms to invest more in R&D, there is a scarcity of empirical studies that provide evidence on whether this will have any effect on firm growth. Clearly, understanding the firm-specific characteristics and activities that determine which Chi 2 1.89e þ 11*** 6.43e þ 12*** 6.54e þ 08*** 1.28e þ 09*** 7.24e þ 11*** *p , 0.10, **p , 0.05, ***p , 0.01.
firms are most likely to grow is essential for designing effective growth policies. Hence, in this paper we questioned whether R&D should be made central for such economic growth policies. Our findings suggest that the set of criteria that determine whether markets reward innovators with a growth premium is a mix between firm size and the different aspects of the firms' innovative activities. Results indicate that the innovation -growth relationship is not as simple as it might appear at first sight and one might arrive at misleading conclusions if they fail to take into account the heterogeneous composition of firms that constitute the industry. In the case of the pharmaceutical industry, evaluated at the industry level, we find that R&D has been effective at boosting firm growth through the whole industry history. However, a closer look into different types of firms reveals that the expected positive impact of R&D only applies to a subset of firms.
More specifically, we find a positive relationship between R&D and firm growth only for small pharmaceutical firms. However, only the small firms that are able to patent persistently are able to reap these growth benefits. For the large firms, on the other hand, R&D investments slow down growth instead of boosting it.
The different impact of innovation for the growth of small and large firms has important implications for government policies that aim to achieve an innovation-led economic growth. The EC's Lisbon Agenda (2000) that has set an R&D target of 3 per cent of GDP has been the overarching theme in EU countries' innovation policies. However, to achieve growth from this spending, we need a more detailed and sophisticated understanding of the conditions under which R&D is most likely to lead to economic growth-and how such conditions differ between industries (e.g. high-tech, medium-tech, low-tech, manufacturing, services, etc.), between periods in the industry life cycle and between different types of firms (e.g. young firms, public firms, high advertisers, etc.). Studies, such as ours, providing evidence of what types of combinations are necessary for R&D to affect growth, and how these combinations differ between sectors, will allow policymakers to better target innovation-led growth policies.
The paper also draws attention to economic returns to R&D in the pharmaceutical industry. Our results provide an additional insight into the highly debated issue of the R&D productivity paradox in this industry by highlighting that the R&D efforts of large pharmaceutical firms are unlikely to drive sales growth. While large firms have been heavily criticized for their low R&D productivity and the lack of truly innovative drug discoveries (Angell, 2005) , there has not been much systematic evidence indicating the economic returns to R&D. These findings also bring a potential explanation into recent decisions by large pharmaceutical firms to close R&D sites such as Pfizer closing its European R&D headquarters in Kent (UK), Merck closing 8 of its 24 R&D centres and AstraZeneca closing its Loughborough and Cambridge R&D sites in 2011. Clearly, the pharmaceutical industry is undergoing a major industrial reorganization driven by falling R&D productivity and the economic returns to R&D. It is essential to capture these important changes in the industrylife cycle literature.
Finally, the paper provides important evidence on the relevance of persistent innovation for firm performance. The innovative persistence literature has mainly concentrated on implications of persistence for the theory of the firm (the representative agent), and the different types of dynamic increasing returns to scale that might lead to persistence, without providing evidence on how and whether persistence affects firm performance. Our results confirm that persistent innovations and persistent patenting may indeed be key for firms to reap economic returns to their R&D efforts.
